Pliant Therapeutics (PLRX) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for Pliant Therapeutics
Is Pliant Therapeutics a buy right now? The alternative data says hold. This PLRX stock analysis is built on the 25+ alternative data signals AltIndex tracks on Pliant Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 58/100: a Hold. The stock trades at $1.15 with a $68M market cap.
The soft spots over the past 90 days: headcount (according to LinkedIn) down 27.0% to 89 employees, business outlook fell 13.3% — now 72% of employees are positive, and web traffic down 9.9% to 5K monthly visits. The rest of the signal set is holding steady, which keeps PLRX at a hold rather than a sell.
PLRX’s broader alt-data profile also covers job postings (3 open roles), X followers (494), and sentiment (100/100). Every signal links to its own page with full history, the PLRX technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on PLRX is just below.
Pliant Therapeutics AI Stock Analysis
Pliant Therapeutics is a biotechnology company focused on discovering and developing novel therapies for fibrotic diseases. The company's core expertise lies in targeting fibrosis pathways to provide effective treatments for diseases that currently lack adequate therapeutic solutions.
Analysis generated August 1, 2026.
Recent Pliant Therapeutics Stock Alerts
|
Pliant Therapeutics | August 18 Price is up by 6.4% in the last 24h. |
|
Pliant Therapeutics | July 20 Price is down by -6.1% in the last 24h. |
|
Pliant Therapeutics | June 29 Employee Rating is down by 5.3% over the last month. |
|
Pliant Therapeutics | June 29 Business Outlook among employees is down by 13.3% over the last month. |
Pliant Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 5K | 9.9% | |
| Job Posts | 3 | 0% | |
| LinkedIn Employees | 89 | 27.0% | |
| Employee Recommend | 48 | 12.7% | |
| Business Outlook | 72 | 13.3% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 6 | 0% | |
| Stocktwits Mentions | 9 | 80.0% | |
| News Mentions | 0 | 100.0% | |
| Stocktwits Subscribers | 2K | 1.6% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 494 | 0% | |
| Youtube Subscribers | 116 | 0.9% | |
| Facebook Followers | 129 | 4.0% | |
| Facebook Engagement | 2 | N/A |
About Pliant Therapeutics (PLRX)
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.
| Price | $1.15 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $68M |
| Year Range | $1 – $2 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Pliant Therapeutics News
View more →
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of DirectorsJuly 13 - GlobeNewswire |
|
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual MeetingMay 21 - GlobeNewswire |
|
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 11 - GlobeNewswire |
|
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare ConferenceMay 6 - GlobeNewswire |
|
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid TumorsApril 30 - GlobeNewswire |
Pliant Therapeutics Earnings & Financial Performance
View all earnings →Pliant Therapeutics Insider Trading Activity
View all →| Kuo Minnie filed to sell 37,806 shares at $0.0. Jan 20 '26 |
| Cheung Lily filed to sell 44,847 shares at $0.0. Jan 20 '26 |
| Coulie Bernard filed to sell 505,601 shares at $0.0. Jan 20 '26 |
| Cummings Keith Lamont filed to sell 297,214 shares at $0.0. Jan 20 '26 |
| Ouimette Mike filed to sell 70,544 shares at $0.0. Jan 22 '25 |
Pliant Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Pliant Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
ApollomicsAPLM |
$23.92 1.6% | $68M | 44 |
 |
OS TherapiesOSTX |
$1.44 2.0% | $68M | 59 |
 |
Cardiff OncologyCRDF |
$0.89 2.0% | $70M | 54 |
 |
DarioHealthDRIO |
$7.18 2.5% | $70M | 46 |
 |
Spero TherapeuticsSPRO |
$1.20 0.8% | $72M | 47 |
Explore Pliant Therapeutics Data
Frequently Asked Questions: Pliant Therapeutics (PLRX)
Pliant Therapeutics has an AltIndex AI Score of 58/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
58/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Pliant Therapeutics (PLRX) stock is $1.15 with a market cap of $68M.
As of today, Pliant Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Pliant Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Pliant Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The PLRX stock price chart above shows Pliant Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Pliant Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Pliant Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
